ABUS · Arbutus Biopharma Corp · Share Buybacks
$4.02
-0.05 (-1.23%)
At close · Nov 20
Return incl. dividend (before tax)
Q3 2024 earnings call transcript
Market Cap
$616.24M
Shares
153.29M
Volume · Nov 20
2.99M
Avg daily vol (3M)
5.19M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$230,000,000
as of 2026-09-30
· from Press release (reviewed)· expired 2026-09-29
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-08-21 | $230,000,000 | — | — | 2026-09-29 expired | Press release , published 2026-08-24 |
| 2026-07-16 | $230,000,000 | — | — | — | 8-K , filed 2026-07-16 |
Key facts
CIK
1447028
CUSIP
03879J100
13F (30d)
221 filings
200 filers
Visit website
Investor relations